Catalent Expands Highly Potent Drug Packaging Capabilities

November 6, 2014
Pharmaceutical Technology Editors

Catalent Pharma Solutions announces additional packaging and storage space for highly potent and cytotocix drugs at Kansas City facility.

Catalent Pharma Solutions has announced that work has commenced to expand its highly potent and cytotoxic clinical drug packaging capabilities within its 450,000 sq ft Kansas City, MO campus.

The expansion will increase the available packaging space for highly potent compounds adding two large packaging suites, a sampling lab, and space for various storage conditions. Segregated and separated from non-potent manufacturing operations, the new 6000 sq ft facility is capable of handling SafeBridge Category 3, 4 and cytotoxic compounds. Completion is expected in January 2015.

Catalent currently has highly potent and cytotoxic drug packaging suites in its clinical supply facility in Bolton, UK.
  
Catalent’s Kansas City campus provides formulation development, small- and large-molecule analytical testing, and clinical and commercial scale manufacturing and packaging of a variety of oral solid dose forms.

Source: Catalent Pharma Solutions